Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
16 Jun 2022 Other relevant information The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs   Download
14 Jun 2022 Announcement of general shareholders’ meeting ROVI releases the information related to its General Shareholders Meeting Download
11 May 2022 On business and financial situation The Company releases the press release related to the first quarter 2022 financial result Download
11 May 2022 On business and financial situation The Company releases the first quarter 2022 financial results presentation Download
11 May 2022 Announcement of general shareholders’ meeting Rovi releases the information related to its 2022 General Shareholders Meeting Download

Pages

Date Title Description PDF
07 Nov 2019 Information on P&L ROVI releases the first nine months 2019 results presentation Download
03 Oct 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the third quarter of 2019 Download
05 Sep 2019 Others on business performance and financial information The Company informs about the construction of a second heparin plant in Granada Download
30 Jul 2019 Information on P&L ROVI releases the first half 2019 results presentation Download
30 Jul 2019 Information on P&L ROVI releases the press release related to the first half 2019 financial results Download

Pages